* In the VANGUARD pivotal phase 3 trial. Patients in the pivotal study and open-label extension study experienced injection-site redness, itching, and bruising.
Adverse reactions occurring in ≥7% of Patients Receiving ANDEMBRY and More Common than Placebo in the Phase 3 VANGUARD Study
Injection-Site Reactions
In VANGUARD and an open-label clinical study, which included 57 patients who rolled over from VANGUARD, 164 patients with HAE received ANDEMBRY 200 mg subcutaneously every month. Injection-site reactions (eg, redness, itching, and bruising) were reported in 23 (14%) patients.
Innovation in Action
Only ANDEMBRY, a monoclonal antibody, inhibits FXIIa at the top of the HAE pathway